RxDoctor Payments Data

Stacia Sackmaster

Nurse Practitioner · Rockford, ILNPI 1912330895

Payments from drug & device makers

$2,846in general payments, 2019–2025

Across 52 payments — averaging $54.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Madrigal Pharmaceuticals$2K
  • AbbVie$349
  • Johnson & Johnson$168
  • Medtronic$90
  • Merck$59
  • Janssen Scientific Affairs, LLC$50
  • plus $322 from 13 others

What the payments were for

  • Consulting fees$1,21543%
  • Travel & lodging$1736%
  • Food & beverage$1,45851%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,846 in reported general payments places this provider in the 90th percentile of 4,869 nurse practitioner providers in Illinois.

See all nurse practitioner providers in Illinois

Medicare billing

Part B allowed, 2024
$74,817
Medicare patients
320
Services billed
2,697

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin67$225,413
RezdiffraResmetirom32$125,421
OcalivaObeticholic Acid12$113,047
CreonLipase/Protease/Amylase20$34,653
LinzessLinaclotide24$18,788
MovantikNaloxegol Oxalate23$14,398
Ursodiol56$7,994
TrulancePlecanatide12$7,709
Dexlansoprazole DrDexlansoprazole24$3,977
SutabSod Sulf/Pot Chloride/Mag Sulf14$2,277
Omeprazole273$2,203
Esomeprazole Magnesium50$1,277
Pantoprazole Sodium119$962
Spironolactone41$613
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl50$567

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$20$233,12379 claims
Madrigal PharmaceuticalsRezdiffra$1,809$125,42132 claims
AbbVieCreon, Linzess$349$53,44144 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,869 nurse practitioner providers in Illinois.

Other nurse practitioner in Rockford

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →